Enzo Q4 Revenues Narrow 12 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Tuesday a 12 percent drop in total revenues for its fiscal fourth quarter.

For the three months ended July 31, the company took in $23.3 million in revenues, down from $26.4 million a year ago. Clinical laboratory services shrank to $14.0 million from $15.9 million, while product revenues retreated to $8.0 million from $8.9 million. Royalty and license fee income was down to $1.3 million from $1.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.